• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Family Health Corner

News That Affects Your Family's Health

FAMILY HEALTH CORNER
News That Affects Your Family's Health

  • Home
  • About/Contact
  • CHILDREN
  • HEALTH NEWS/TRENDS
  • INSURANCE
  • MEN
  • MENTAL HEALTH
  • WOMEN

First Patient in US Dosed for New Phenylketonuria Gene Therapy

June 5, 2021 by Staff Reporter


Trial treatment represents promising possibilities for other disorders

On Jun 3, 2021

A geneticist with Morristown-based Atlantic Health System’s physician network, Atlantic Medical Group, recently treated the first patient in the United States in a clinical trial with a genetic therapy developed by BioMarin, designed to help patients who are not able to metabolize phenylalanine, an amino acid found in nearly all proteins.

Darius Adams, MD, medical director of the Jacobs Levy Genomic Medicine and Research Program at Atlantic Health System and division chief of pediatric genetics, provided the therapy as part of a clinical trial that includes Atlantic Health System and currently two other hospitals worldwide.

The investigational therapy was given intravenously to an adult diagnosed with phenylketonuria (PKU), a genetic disorder that affects people from birth. The patient will be monitored for five years to determine the long-term safety and efficacy of the treatment.

“We are excited to be on the forefront of studying this new therapy that could radically improve the lives of so many people,” said Dr. Adams. “The impacts of phenylketonuria stretch further than simply dietary concerns, and this therapy offers great promise to these individuals to possibly having a better quality of life, throughout their lifetime.”

Dr. Adams’s work is supported by his colleagues, Christina Flora, research coordinator, and Lindsay Schumacher, dietician.

Newborn screening began with the development of a blood test for phenylketonuria in the 1960s. The test was given to babies soon after birth, in order to allow physicians and dietitians to begin dietary therapy as needed as soon as possible.

While a certain amount of phenylalanine is needed by the body, an overabundance of it can cause a range of problems, from behavioral and intellectual disorders, to severe brain damage.

To date, patients who have PKU have had limited treatments available to them, primarily in the form of specific dietary restrictions that begin in a person’s infancy or daily injections when older. Due to an abundance of carbohydrates replacing protein in these altered diets, obesity can often be a side effect. Maintaining these restrictions can become challenging later in life, such as during college years and depending upon a person’s profession in adulthood.

The disorder is caused by a genetic mutation in a person’s DNA. The gene therapy carries a gene sequence to replace it, targeting the liver cells and releasing the genetic material. The body then “reads” the gene sequence and makes a copy of the enzyme that can break down the phenylalanine.

“We are in an exciting period of genomic medicine, exploring the ability to help correct genetic diseases,” said Dr. Adams. “We are hopeful that the success of this gene therapy will be the doorway to solving many more common health disorders.”

Dr. Adams’s colleagues throughout at Atlantic Health System are enthusiastically supportive of his participation in the trial.

“At Goryeb Children’s Hospital and Children’s Health throughout Atlantic Health System, we strive to make patients’ lives healthier from the very earliest stages of childhood,” said Walter Rosenfeld, MD, chair of pediatrics. “While this initial trial involved an adult, its success offers great hope to parents and patients of all ages as an important new tool that could have a huge impact on their lives.”

The Jacobs Levy Genomic Medicine and Research Program at Atlantic Health System provides individualized, full-spectrum genomic care, designed to ensure that patients receive the medical and health services that will most benefit them.

This includes diagnostic testing based on symptoms, family history and result consultation with a licensed genetic counselor to thoroughly explain positive results and discuss further medical care options. For chronic patients, care includes follow up visits, blood level monitoring and medication management.

The genomic program treats and follows numerous patients diagnosed with PKU, with doctors and a dietitian helping them to closely monitor and track their level of phenylalanine, maintain their dietary modifications and prescribe injectable treatment.

To access more business news, visit NJB News Now.

Related Articles:

[ad_2]
Originally Appeared Here

Filed Under: CHILDREN

Primary Sidebar

More to See

Medical startup has Stonington native in mind

Oct. 6—When over 100 people gather on Tuesday, Oct. 12, at Stonington Country Club for the first Andrew Heylmun Invitational golf tournament, they'll … [Read More...] about Medical startup has Stonington native in mind

Walking your way: NAMI hosting virtual walk for mental health this weekend | News, Sports, Jobs

MARQUETTE — There’s never a bad time to think about your mental health: Where it stands, how you can improve it, and where to go for help if you need … [Read More...] about Walking your way: NAMI hosting virtual walk for mental health this weekend | News, Sports, Jobs

18 ft Purple Crush Water Slide Rental

https://abouttobounce.com - BOOK YOUR Inflatable Party Rental from About To Bounce Inflatables, TODAY! Inflatable Bounce House and Inflatable Water … [Read More...] about 18 ft Purple Crush Water Slide Rental

Privacy Policy | Terms and Conditions | About/ Contact
As an Amazon Associate I earn from qualifying purchases.
Copyright © 2022 · FAMILY HEALTH CORNER . Log in